TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01638208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
Study: NCT03467490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DED self-management
Description: This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
Study: NCT00975819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: liquid dosing based on trough levels
Study: NCT01920893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for dupilumab)
Description: Solution for injection; Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection; Subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Nasal spray, 2 actuations in each nostril twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Nasal spray, 2 actuations in each nostril twice daily.
Study: NCT03100370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Cathodal Stimulation
Description: 2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study: NCT01683513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh agonist +1500E hCG
Description: ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
Study: NCT02252601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFDT test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFDT test
Study: NCT03100370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Cathodal Stimulation
Description: 2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Cathodal Stimulation
Description: 2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study: NCT02252601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFDT test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFDT test
Study: NCT02252601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure tone Audiogram
Study: NCT01372501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobarrier Liner
Description: Medical device placed endoscopically in the duodenum
Study: NCT00528814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Hand Sanitizer
Description: Active Hand Sanitizer
Study: NCT03030092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Strength Training
Description: leg pres and abduction exercises
Study: NCT01758367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deciatbine(DAC)
Study: NCT00983944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV or orally
Study: NCT03100370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Sham Stimulation
Description: 2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study: NCT00983944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV or orally
Study: NCT02345811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire
Description: silicone-hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: contact lens
Study: NCT03366376

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT with hippocampus-sparing and SIB
Description: Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy
Study: NCT03633487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 1200 mg ER Bi-Layer tablet
Study: NCT00660530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate Chewable Product
Description: Lanthanum carbonate 1 g to be chewed, three times daily with meals
Study: NCT02252601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure tone Audiogram

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pure tone Audiogram

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure tone Audiogram
Study: NCT02118597

Intervention type: DRUG
Intervention: Boceprevir
Description: Boceprevir administered according to corresponding summary of product characteristics (SmPC).
Study: NCT00983944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV or orally
Study: NCT00638989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 150 mg (intravenous)
Description: A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 150 mg (subcutaneous)
Description: A single dose of CAT-354 150 mg injection subcutaneously on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 300 mg (subcutaneous)
Description: A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
Study: NCT01228435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: Given intravenously twice weekly for 2 weeks followed by 10 day off treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
Study: NCT02886442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard adhesive strip
Description: This is a standard adhesive strip (hydrocolloid)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed adhesive strip
Study: NCT02118597

Intervention type: DRUG
Intervention: Simeprevir
Description: Simeprevir administered according to corresponding summary of product characteristics (SmPC).

Intervention type: DRUG
Intervention: Pegylated Interferon (Peginterferon) Alfa-2a
Description: Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
Study: NCT00660530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate crushed powder
Description: Lanthanum carbonate (Fosrenol) 1 g crushed into a fine powder, three times daily with meal
Study: NCT02118597

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to corresponding summary of product characteristics (SmPC).
Study: NCT03184363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium Botulinum A Toxin
Description: Clostridium Botulinum A Toxin
Study: NCT01355263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron and vitamin a
Study: NCT01283906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuGard
Description: Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Rinse
Description: Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
Study: NCT01903395

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling
Description: Nurse-led telephone counselling to double the utilization of preventive colonoscopy
Study: NCT01512849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 Low
Description: Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284 High
Description: High
Study: NCT04659447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: 36 ml of peripheral blood is extracted from patients, and 4 ml of 3.8% sodium citrate is added for anticoagulation. After centrifugation for 2 times, 4 ml platelet-rich plasma will be prepared.Four semitendinosus tendons and gracilis tendons are prepared.
Study: NCT02102126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Study: NCT02159118

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual bone marrow aspiration and biopsy device
Description: Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powered bone marrow aspiration and biopsy device
Description: Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
Study: NCT01742572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Change in dietary intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Change in dietary intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Change in dietary intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Change in dietary intake

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Change in dietary intake
Study: NCT04336371

Intervention type: DIAGNOSTIC_TEST
Intervention: Self-administered questionnaires
Description: Self-administered questionnaires by the patient will be given during visits in the following order:the self-administered questionnaires concerning the announcement consultation will be completed by the patient after consultation waiting room; self-questionnaires will be given in just before the operation waiting room (D0) just before the suture removal points (J10) and just before the follow-up visit (M3).
Study: NCT02523131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceM
Description: The automated closed loop system (FlorenceM) will consist of:~* Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic insulin pump 640G
Description: Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
Study: NCT03671707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief AWARD advice
Description: Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~1. Ask: smokers will be asked about their smoking behaviour~2. Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~3. Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~4. Refer smokers to smoking cessation services if they agree.~5. Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy sampling
Description: Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active referral
Description: Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very brief advice
Description: Subjects will receive general advice to quit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: Subjects will receive a standard leaflet on perinatal smoking by Department of Health
Study: NCT04504890

Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Nystagmograph used to measure eye movement

Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Nystagmograph used to measure eye movement

Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Nystagmograph used to measure eye movement

Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Nystagmograph used to measure eye movement
Study: NCT01296074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: 500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
Study: NCT01890395

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
Study: NCT03097575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG Intervention
Description: Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Imaging
Description: A near-infrared camera device will be used to detect indocyanine green following injection.
Study: NCT04490980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: butorphanol
Description: Observed group:Intravenous drip of Butorphanol in patients after cesarean section;control group: intravenous drip of saline in patients after cesarean section
Study: NCT00580125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 5 mg, oral capsule, once daily for 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral capsule, once daily for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole 15 mg, oral capsule, once daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 15 mg, oral capsule, once daily for 21 days
Study: NCT01183130

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compliance monitoring with electronic device
Description: Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
Study: NCT00580125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00217830
Description: PF-00217830 2 mg, oral capsule, once daily for 21 days
Study: NCT00320749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Will be give on days 8-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Will be given on days 1 and 8,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A fixed dose rate will be give on days 8 and 15.
Study: NCT03454867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemofiltration
Study: NCT03454867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard acute ischemic stroke treatment
Study: NCT01857349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlora Prep
Description: Surgical Scrub skin preparation
Study: NCT03454867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard acute ischemic stroke treatment
Study: NCT03627312

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fruit juice drink only
Study: NCT01857349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dura Prep
Description: Surgical Scrub skin preparation
Study: NCT03627312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme
Study: NCT01924312

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Heart Health Intervention
Description: A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Health Intervention
Description: A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
Study: NCT03627312

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Young Offenders Intervention Programme
Study: NCT01170754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-3350 and Gatorade
Description: 255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely 4 liters
Description: Golytely 4 liters
Study: NCT00974909

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC neuromodulation system
Description: Urgent PC neuromodulation system

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Urgent PC neuromodulation system
Description: Urgent PC neuromodulation system (sham)
Study: NCT01395433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 2 x 10 mg, single dose
Study: NCT01562405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-011
Description: Injection every 28 days, dose escalation levels from 15-45 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15 to 25 mg days 1-21, given orally
Study: NCT01395433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 2 x 10 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 1 x 20 mg, single dose
Study: NCT03465592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV
Study: NCT03864471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCOACDM
Description: The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
Study: NCT01689129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine new formulation (HOE901)
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901) (Lantus)
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT01108133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg HydrocortisoneHöchst
Description: 10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01830660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04357392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
Study: NCT02450032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT